EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Relay Therapeutics's enterprise value is $-176.29 Mil.
Relay Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-373.07 Mil. Therefore, Relay Therapeutics's EV-to-EBITDA for today is 0.47.
The historical rank and industry rank for Relay Therapeutics's EV-to-EBITDA or its related term are showing as below:
RLAY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.37 Med: -2.98 Max: 0.87
Current: 0.47
During the past 7 years, the highest EV-to-EBITDA of Relay Therapeutics was 0.87. The lowest was -93.37. And the median was -2.98.
RLAY's EV-to-EBITDA is ranked better than 78.84% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs RLAY: 0.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Relay Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Relay Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Relay Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Relay Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's EV-to-EBITDA falls into.
Relay Therapeutics's current Enterprise Value is $-176.29 Mil.
Relay Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-373.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Relay Therapeutics's PE Ratio (TTM) for today is calculated as:
Relay Therapeutics's share price for today is $2.855.
Relay Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Relay Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLAY has been successfully added to your 